Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464919 | 0.89 | MAPT (0.50) | SIGMAR1ALDH1A1CHRM5CHRM3TDP1 | |
| SCHEMBL20355864 | 0.86 | SIGMAR1 (0.49) | SIGMAR1PIK3CDALDH1A1CYP1A2TDP1 | |
| SCHEMBL27976690 | 0.84 | MAPT (0.58) | ALDH1A1CHRM5CHRM3MAPTMEN1 | |
| SCHEMBL20374376 | 0.84 | SIGMAR1 (0.50) | SIGMAR1PIK3CDCYP1A2TDP1KMT2A | |
| SCHEMBL7144885 | 0.82 | MAPT (0.61) | ALDH1A1CHRM5CHRM3CYP1A2MAPT | |
| SCHEMBL24530727 | 0.81 | CHRM5 (0.44) | SIGMAR1ALDH1A1CHRM5CHRM3TDP1 | |
| SCHEMBL16809207 | 0.81 | SIGMAR1 (0.56) | SIGMAR1PIK3CDALDH1A1CYP1A2TDP1 | |
| SCHEMBL19928689 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CHRM3MAPTMEN1MAPK1 | |
| SCHEMBL13396798 | 0.78 | SMN1; SMN2 (0.61) | ALDH1A1MEN1KMT2AHTTSMN1; SMN2 | |
| SCHEMBL13588710 | 0.77 | PIK3CD (0.56) | SIGMAR1PIK3CDALDH1A1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-9908872-B2 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186780-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4181/4885PIK3CD 354/4885ALDH1A1 4199/4885 |
| US-20180194739-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | IRAK1, IRAK4, IRAK2 | SIGMAR1 4097/4885PIK3CD 338/4885ALDH1A1 3752/4885 |
| US-10633348-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SIGMAR1 4097/4885PIK3CD 338/4885ALDH1A1 3752/4885 |
| US-10597387-B2 | Methods to treat lymphoplasmacytic lymphoma | IRAK1, IRAK4, IRAK2 | SIGMAR1 4181/4885PIK3CD 354/4885ALDH1A1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.